Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of the Blog: Start-Up February 2008

This article was originally published in Start Up

Executive Summary

Best of the Blog is a monthly column highlighting the best of our online content at In February, Windhover's staff posted 52 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory, and commercial news.

You may also be interested in...

Acceleron Pharma Inc.

Few drugs have succeeded in accelerating bone and muscle growth because of the complexity of delivering compounds systemically. Acceleron Pharma hopes to overcome these problems with first-in-class agents to release the brakes holding back the endogenous processes that encourage this growth. The approach Acceleron is taking will allow for systemic administration and should produce effects on the entire skeletal system--not just a local effect.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

CNS IPOs Follow Broad Industry Trends

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts